1. Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. (1st June 2021) Authors: Kumar, Princy; Johnson, Margaret; Molina, Jean-Michel; Rizzardini, Giuliano; Cahn, Pedro; Bickel, Markus; Wan, Hong; Xu, Zhi Jin; Morais, Cristiana; Sklar, Peter; Greaves, Wayne Journal: Journal of acquired immune deficiency syndromes Issue: Volume 87:Number 2(2021) Page Start: 801 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. (1st June 2021) Authors: Kumar, Princy; Johnson, Margaret; Molina, Jean-Michel; Rizzardini, Giuliano; Cahn, Pedro; Bickel, Markus; Wan, Hong; Xu, Zhi Jin; Morais, Cristiana; Sklar, Peter; Greaves, Wayne Journal: Journal of acquired immune deficiency syndromes Issue: Volume 87:Number 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. (August 2017) Authors: Bruchfeld, Annette; Roth, David; Martin, Paul; Nelson, David R; Pol, Stanislas; Londoño, Maria-Carlota; Monsour, Howard; Silva, Marcelo; Hwang, Peggy; Arduino, Jean-Marie; Robertson, Michael; Nguyen, Bach-Yen; Wahl, Janice; Barr, Eliav; Greaves, Wayne Journal: Lancet gastroenterology and hepatology Issue: Volume 2:Number 8(2017) Page Start: 585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre‐existing renal disease. Issue 12 (12th May 2017) Authors: Reddy, K. Rajender; Roth, David; Bruchfeld, Annette; Hwang, Peggy; Haber, Barbara; Robertson, Michael N.; Barr, Eliav; Greaves, Wayne Journal: Hepatology research Issue: Volume 47:Issue 12(2017) Page Start: 1340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Issue 10003 (17th October 2015) Authors: Roth, David; Nelson, David R; Bruchfeld, Annette; Liapakis, AnnMarie; Silva, Marcelo; Monsour, Howard; Martin, Paul; Pol, Stanislas; Londoño, Maria-Carlota; Hassanein, Tarek; Zamor, Philippe J; Zuckerman, Eli; Wan, Shuyan; Jackson, Beth; Nguyen, Bach-Yen; Robertson, Michael; Barr, Eliav; Wahl, Ja... Journal: Lancet Issue: Volume 386:Issue 10003(2015) Page Start: 1537 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. (26th November 2018) Authors: Kumar, Princy; Johnson, Margaret; Molina, Jean-Michel; Rizzardini, Giuliano; Cahn, Pedro; Bickel, Markus; Mallolas, Josep; Zhou, Yan; Morais, Cristiana; Kumar, Sushma; Sklar, Peter; Hanna, George J; Hwang, Carey; Greaves, Wayne Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S759 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial. (15th August 2018) Authors: Cahn, Pedro; Sax, Paul E.; Squires, Kathleen; Molina, Jean-Michel; Ratanasuwan, Winai; Rassool, Mohammed; Bloch, Mark; Xu, Xia; Zhou, Yan; Homony, Brenda; Hepler, Deborah; Teppler, Hedy; Hanna, George J.; Nguyen, Bach-Yen; Greaves, Wayne Journal: Journal of acquired immune deficiency syndromes Issue: Volume 78:Number 5(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. (1st August 2019) Authors: Johnson, Margaret; Kumar, Princy; Molina, Jean-Michel; Rizzardini, Giuliano; Cahn, Pedro; Bickel, Markus; Mallolas, Josep; Zhou, Yan; Morais, Cristiana; Kumar, Sushma; Sklar, Peter; Hanna, George J.; Hwang, Carey; Greaves, Wayne Journal: Journal of acquired immune deficiency syndromes Issue: Volume 81:Number 4(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗